Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Current Topics in Microbiology and Immunology
|
January 1, 1995
Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies
K D Robertson, J Barletta, D Samid, et al.
Seminars in Cancer Biology
|
August 1, 1996
Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma
R F Ambinder, K D Robertson, S M Moore, et al.
Cancer Research
|
September 15, 2000
The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells
G Liang, K D Robertson, C Talmadge, et al.
Blood
|
March 7, 1998
Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue
Q Tao, K D Robertson, A Manns, et al.
Journal of Virology
|
August 8, 1998
The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive
Q Tao, K D Robertson, A Manns, et al.
Oncogene
|
October 18, 2006
Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer
S Zhong, C R Fields, N Su, et al.
Nucleic Acids Research
|
April 25, 2000
Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells
K D Robertson, K Keyomarsi, F A Gonzales, et al.
Molecular and Cellular Biology
|
November 1, 1995
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial
K D Robertson, S D Hayward, P D Ling, et al.
The American Journal of Pathology
|
August 6, 1999
Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis
Q Tao, L J Swinnen, J Yang, et al.
Blood
|
October 15, 1996
CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease
K D Robertson, A Manns, L J Swinnen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Current Topics in Microbiology and Immunology
|
January 1, 1995
Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies
K D Robertson, J Barletta, D Samid, et al.
Seminars in Cancer Biology
|
August 1, 1996
Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma
R F Ambinder, K D Robertson, S M Moore, et al.
Cancer Research
|
September 15, 2000
The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells
G Liang, K D Robertson, C Talmadge, et al.
Blood
|
March 7, 1998
Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue
Q Tao, K D Robertson, A Manns, et al.
Journal of Virology
|
August 8, 1998
The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive
Q Tao, K D Robertson, A Manns, et al.
Oncogene
|
October 18, 2006
Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer
S Zhong, C R Fields, N Su, et al.
Nucleic Acids Research
|
April 25, 2000
Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells
K D Robertson, K Keyomarsi, F A Gonzales, et al.
Molecular and Cellular Biology
|
November 1, 1995
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial
K D Robertson, S D Hayward, P D Ling, et al.
The American Journal of Pathology
|
August 6, 1999
Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis
Q Tao, L J Swinnen, J Yang, et al.
Blood
|
October 15, 1996
CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease
K D Robertson, A Manns, L J Swinnen, et al.
Page
of 3